Hamburg University
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The Hamburg University Department of Chemistry conducts studies that evaluate new injection devices and visual assessment methods for facial aesthetic conditions such as glabellar lines and forehead wrinkles, focusing on safety and precise measurement.
- Safety and tolerability of novel botulinum toxin formulations
- Evaluation of diffusion characteristics in facial muscles
- Development of live visual assessment tools for treatment outcomes
- Standardized skin and sweating tests for diagnostic accuracy
This work aims to improve diagnostic precision and equipment performance for non‑invasive cosmetic therapies.
Therapeutics
Clinical trials at the site assess innovative therapeutic agents, including IPN10200 and NT 201, for treating moderate to severe facial lines and platysma prominence, with the goal of expanding non‑surgical options.
- Single‑dose botulinum toxin treatments for glabellar and forehead lines
- Combination therapy using FTP‑002/FTP‑501
- Comparative efficacy of IPN10200 versus placebo
- Long‑term safety evaluation of NT 201
Results are intended to provide safe and effective alternatives for patients seeking facial rejuvenation.
Physical Phenomena
Research explores the diffusion characteristics of botulinum toxin preparations and related skin responses, measuring factors such as anhidrotic halo size and sweating activity to understand underlying physical processes.
- Measurement of anhidrotic halo dimensions after toxin injection
- Analysis of protein‑complex effects on toxin spread
- Assessment of muscle contraction dynamics during treatment
- Quantification of standardized sweating activity in test areas
Insights from these studies guide formulation improvements and help predict clinical performance.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Ipsen Innovation2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ipsen Innovation2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hamburg University
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| BOTOX® (Botulinum toxin type A) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Oct 2023 | Oct 2025 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Botulinum Toxin Type A | 3 | Unknown | 2023-10-11 | 2024-11-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.